Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Core Insights - Celldex has appointed Teri Lawver as Senior Vice President and Chief Commercial Officer, succeeding Richard Wright who is retiring after over a decade of service [1][2] - Teri Lawver brings 30 years of experience in global healthcare, particularly in biopharmaceuticals and medical technology, with a strong background in immunology and inflammation [2][3] - Lawver's previous roles include Chief Commercial Officer at Dexcom, where she managed $4 billion in annual revenue, and significant positions at Johnson & Johnson, including Worldwide Vice President for Janssen Immunology [2] Company Overview - Celldex is focused on advancing immunology to develop novel antibody-based therapies aimed at improving outcomes for patients with allergic, inflammatory, and autoimmune disorders [3] - The company is preparing for the potential launch of barzolvolimab and is advancing its broader pipeline of therapies [2][3]